Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Medicine (Baltimore) ; 102(21): e33862, 2023 May 26.
Artículo en Inglés | MEDLINE | ID: mdl-37233438

RESUMEN

BACKGROUND: Physicians' seniority has always been the focus of patients. Silver needle therapy (SNT) has been applied for more than 60 years. It is similar to moxibustion and has a good therapeutic effect on soft tissue pain. This study aimed to determine the influence of physicians' seniority on the efficacy of SNT for patients with low back fasciitis. METHODS: This was a prospective cohort study at the Affiliated Hospital of Qingdao University. Patients diagnosed with low back fasciitis were split into junior physician (JP) and senior physician (SP) groups (n = 30) based on the seniority of the physician. The numerical rating scale (NRS) was administered during the SNT, and operation time was recorded. The NRS, Oswestry Disability Index (ODI), and Short-Form 12 of quality of life (SF-12) scores at 1, 2, 6, and 12 months after the treatment and autonomic nervous system (ANS) activity were also observed. RESULTS: Compared with the SP group, the NRS score during the SNT (5.20 ±â€…0.71 vs 2.53 ±â€…0.94) and operation time (11.7 ±â€…1.6 minutes vs 6.8 ±â€…1.1 minute) were higher in the JP group (P < .05). The NRS, ODI score, SF-12 score, and ANS activity after treatment were not significantly different between SP and JP groups. Additionally, in the multivariate linear regression analysis model, the physicians' seniority was an independent factor affecting the NRS score during the SNT and operation time (P < .05). CONCLUSION: SNT could attenuate the pain of patients with low back fasciitis in the short and long term without severe complications. The physicians' seniority did not influence the efficacy of SNT, but the JP group showed an increased operation time and a higher degree of pain during the operation.


Asunto(s)
Calidad de Vida , Plata , Humanos , Estudios Prospectivos , Estudios de Cohortes , Dolor , Resultado del Tratamiento , Vértebras Lumbares/cirugía
2.
Mol Med Rep ; 12(5): 6718-26, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26352430

RESUMEN

The aim of the present study was to evaluate the effect of astragalosides (ASTs) on angiogenesis, as well as the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) following myocardial infarction (MI). MI was induced in rats by ligation of the left coronary artery. Twenty­four hours after surgery, the rats were divided into low­dose, high­dose, control and sham surgery groups (n=8 per group). The low­ and high­dose groups were treated with ASTs (2.5 and 10 mg/kg/day, respectively, via intraperitoneal injection), while, the control and sham surgery group rats received saline. Serum levels, and mRNA and protein expression levels of VEGF and bFGF, as well as the microvessel density (MVD) were determined four weeks post­treatment. Twenty­four hours post­surgery, VEGF and bFGF serum levels were observed to be comparable between the groups; while at four weeks, the VEGF and bFGF levels were higher in the AST­treated rats (P<0.01). Similarly, VEGF and bFGF mRNA and protein expression levels were higher following AST treatment (P<0.05). No difference in VEGF mRNA expression between the low­ and high­dose groups was noted, however, an increase in the bFGF expression levels was detected in the high­dose group. Newly generated blood vessels were observed following MI, with a significant increase in MVD observed in the AST­treated groups (P<0.05). AST promotes angiogenesis of the heart and increases VEGF and bFGF expression levels. Thus, it is hypothesized that increased VEGF and bFGF levels may contribute to the AST­induced increase in angiogenesis in rat models of MI.


Asunto(s)
Inductores de la Angiogénesis/farmacología , Factor 2 de Crecimiento de Fibroblastos/fisiología , Infarto del Miocardio/tratamiento farmacológico , Neovascularización Fisiológica/efectos de los fármacos , Saponinas/farmacología , Factor A de Crecimiento Endotelial Vascular/fisiología , Animales , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/fisiopatología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Expresión Génica , Masculino , Microvasos/fisiopatología , Infarto del Miocardio/fisiopatología , Miocardio/patología , Ratas Wistar , Triterpenos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA